Merck Reports the P-III (KEYNOTE-811) Study Data of Keytruda Plus Trastuzumab and Chemotherapy for G/GEJ Adenocarcinoma
Shots:
- The P-III (KEYNOTE-811) study assesses Keytruda + trastuzumab & CT vs PBO + trastuzumab & CT as a 1L treatment of locally advanced unresectable or metastatic HER2+ G/GEJ adenocarcinoma
- The final analysis depicted an improved OS among the ITT population along with advantages in patients with PD-L1-expressing tumors. The study already met the dual 1EP of PFS, highlighted at ESMO 2023
- Additionally, Keytruda + trastuzumab, fluoropyrimidine & Platin based CT received accelerated approval for the same indication supported by the ORR & DoR results from the KEYNOTE-811 study. Complete approval will be based on the final analysis verification
Ref: Merck | Image: Merck
Related News:- GV20 Therapeutics Collaborates with Merck to Evaluate GV20-0251 + KEYTRUDA in Patients with Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
